bioMérieux - First-Half Results at June 30, 2012

04 September, 2012

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today to approve the consolidated financial statements for the six months ended June 30, 2012.

The meeting was chaired by Jean-Luc Belingard and attended by the Statutory Auditors, who had performed a limited review of the financial statements.

Solid financial performance:

  • €128 million in operating income before non-recurring items, up 6.5%
  • Strong increase in cash flow

Faster expansion in emerging markets:

  • India: acquisition of molecular biology specialist RAS
  • Emerging 7*: organic sales growth of 24%
  • bioMérieux China: now the Group’s third largest company
Pioneering Diagnostics